Syngene International announced key board appointments following its board meeting held on April 29, 2026. The biotechnology services company approved the appointment of two new independent directors and the reappointment of an existing director, subject to shareholder approval.

Board Appointments and Reappointments

Based on recommendations from the Nomination & Remuneration Committee, the board approved three significant directorial changes:

The 33rd Annual General Meeting is scheduled to be held on July 29, 2026.

New Director Profiles

Mr. Vijaya Chandru

Vijaya Chandru brings over 25 years of deep-tech innovation experience as a leading academic-entrepreneur. He holds a PhD in Operations Research from Massachusetts Institute of Technology and specializes in decision sciences, optimization, geometry, logic, and computational biology.

His entrepreneurial achievements include co-founding multiple technology companies:

• Strand Life Sciences (2000)
• PicoPeta Simputers (2001)
• Yantri Labs Inc. (2018)
• CRISPRBITS

Chandru serves on faculty at prestigious institutions including National Centre for Biological Sciences, Indian Institute of Science, and Harvard T.H. Chan School of Public Health. In 2024, the American Association for the Advancement of Science elected him Fellow for contributions to theoretical computer science, computational biology, and technology for social good. The World Economic Forum named him a Technology Pioneer in 2006.

Mr. Arun Chandavarkar

Arun Chandavarkar retired as CEO & Joint Managing Director of Biocon Limited on November 30, 2019, after a distinguished 29-year career. During his tenure, he played an instrumental role in transforming Biocon from an enzymes business into a globally recognized biopharma company.

His key contributions at Biocon included:

• Leading the company's 2004 IPO
• Establishing biologics partnerships
• Overseeing major R&D and infrastructure investments
• Managing the divestment of the enzymes business
• Implementing organizational restructuring initiatives

Chandavarkar holds a B.Tech. in Chemical Engineering from Indian Institute of Technology Bombay and a PhD in Chemical Engineering from Massachusetts Institute of Technology. He previously served as Chairperson of the biotechnology committee at Confederation of Indian Industry and currently serves as a non-executive director at Biocon Biologics and an independent director at Mynvax Private Limited.

Continuing Leadership

Ms. Vinita Bali

Vinita Bali's reappointment extends her valuable contribution to Syngene's board. She brings extensive global business leadership experience, having served as Chief Executive Officer & MD of Britannia Industries Ltd. from 2005 to 2014. Her international experience includes senior roles at The Coca-Cola Company and Cadbury Schweppes Plc across multiple countries including the UK, Nigeria, South Africa, USA, and Chile.

Currently, she serves as Non-Executive Director on global boards of SATS Ltd and Cognizant Technology Solutions, and in India, she serves on the board of Bajaj Auto Limited. At Syngene, she actively participates as a member of the Nomination & Remuneration Committee, Audit Committee, and Corporate Social Responsibility Committee.

Regulatory Compliance

The company confirmed compliance with SEBI regulations, stating that all three directors are not debarred from holding director positions by SEBI or any other authority. The appointments align with SEBI letter dated June 14, 2018, and NSE Circular dated June 20, 2018, reference number NSE/CML/2018/24.

All appointments require shareholder approval and will be presented at the upcoming Annual General Meeting for formal ratification.

Syngene International has announced the allotment of 7,29,727 equity shares to the Syngene Employee Welfare Trust under the Syngene Long Term Incentive Performance Share Unit Plan 2023. The Board of Directors approved the allotment at its meeting held on April 29, 2026, in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Share Capital Impact

Consequent to the allotment, the company's paid-up share capital has increased from Rs. 402,93,94,200, comprising 40,29,39,420 equity shares of Rs. 10 each, to Rs. 403,66,91,470, comprising 40,36,69,147 equity shares of Rs. 10 each. The shares have been allotted at an exercise price of Rs. 10 per share with no premium.

Key Allotment Details

Regulatory Compliance and Listing

The equity shares allotted pursuant to the exercise of Performance Share Units rank pari-passu with the existing equity shares of the company. The shares are listed on both the National Stock Exchange of India Limited and BSE Limited. The company has confirmed that listing fees have been paid, and there is no lock-in applicable to the allotted shares.

Previous Approvals

The regulatory filing reveals that the company had previously received approvals for share allotments under the same plan. For 22,00,000 equity shares, BSE approval was received on July 26, 2023, and NSE approval on the same date. For an additional 45,29,000 equity shares, both exchanges provided approval on August 22, 2025.